Belite Bio, Inc. (NASDAQ: BLTE) has priced an underwritten public offering of 2,272,727 American Depositary Shares (ADSs) at $154.00 per ADS, with a 30-day option for underwriters to purchase up to 340,909 additional ADSs. The company expects gross proceeds of approximately $350 million before underwriting discounts and expenses. The offering is significant because it provides capital for Belite Bio to advance its lead candidate, Tinlarebant, through pivotal trials and prepare for potential commercialization.
Belite Bio plans to use the net proceeds for commercialization preparation, pipeline development, and general corporate purposes. The company's focus is on degenerative retinal diseases with high unmet medical need, including Stargardt disease type 1 (STGD1) and geographic atrophy (GA) in advanced dry age-related macular degeneration (AMD). Tinlarebant, an oral therapy designed to reduce the accumulation of bisretinoid toxins in the eye, has completed a Phase 3 trial (DRAGON) in adolescent STGD1 subjects and is currently being evaluated in a Phase 2/3 trial (DRAGON II) and a Phase 3 trial (PHOENIX) for GA.
The underwritten public offering is being managed by Morgan Stanley & Co. LLC, Leerink Partners, BofA Securities, and Cantor as joint active book-running managers, with H.C. Wainwright & Co. as lead manager and Maxim Group LLC and Titan Partners Group as co-managers. The full details of the offering are available in the press release at https://ibn.fm/utfbg.
Belite Bio is a clinical-stage drug development company committed to advancing novel therapeutics for retinal diseases. The company's pipeline addresses conditions that currently have limited treatment options, making this financing crucial for moving Tinlarebant toward regulatory approval. More information about Belite Bio can be found at https://belitebio.com/.
The capital raise comes at a pivotal time for Belite Bio, as it seeks to bring a much-needed oral therapy to patients with Stargardt disease and geographic atrophy. The success of its ongoing trials and subsequent commercialization could significantly impact the treatment landscape for these debilitating conditions.
